Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved daratumumab and hyaluronidase-fihj, marketed as Darzalex Faspro, for adults with high-risk smoldering multiple myeloma.
The approval is important because smoldering myeloma sits between asymptomatic precursor disease and active multiple myeloma.
Treating earlier can change the disease trajectory, but it also raises questions about patient selection, risk scoring and long-term benefit.
Why It Matters
Earlier intervention in precursor conditions can reshape hematology care, but it depends on identifying patients whose risk justifies treatment.
What to Watch
Watch real-world risk stratification, duration of therapy and long-term progression outcomes.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDASmoldering Multiple MyelomaDaratumumabHematology